Please contact our sales representative to learn more information about this reagents.
Background
Gevokizumab is an experimental monoclonal antibody, developed by XOMA Corporation, with allosteric modulating properties. Gevokizumab binds to interleukin-1 beta (IL-1 beta), a pro-inflammatory cytokine, and downmodulates the cellular signaling events that produce inflammation. IL-1 beta has been implicated in cardiovascular conditions, lung cancer, and auto-inflammatory diseases.